What is ASND's five-year median P/E?

There are not enough weekly readings yet for a five-year median P/E.

Does a low historical rank mean a stock is a buy?

No. The rank compares ASND only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.

Ascendis Pharma A/S (ASND) valuation history

Health Care

$253.00

Latest weekly close · Market cap $16.6B

Ascendis Pharma's P/E of 19.4x does not have enough weekly history to rank yet (as of Oct 30, 2026).

Forward P/E 25.3× (analyst estimates, not ranked).
No P/S: recent financial data is missing.
No EV/Sales: recent financial data is missing.
No EV/EBITDA: recent financial data is missing.

No P/E chart for ASND right now

ASND has no weekly P/E history to chart yet.

P/E

n/mnot ranked

P/E needs more weekly history to be ranked.

Growth, last 12 months vs the year before

Revenue: +115%
EPS: n/m

Health Care peers on P/E

Each percentile compares a stock with its own last five years.

Compare ASND with peers

Health Care peers of ASND on P/E
Stock	P/E	Versus its own history	5-year percentile
ABBVAbbVie	82.1×	Above its usual range	77
AMGNAmgen	28.6×	Above its usual range	80
ARWRArrowhead Pharmaceuticals Inc	n/m	Not ranked	n/m, not ranked
BIIBBiogen	107.6×	Historically high	100
BMRNBioMarin Pharmaceutical Inc	155.4×	Within its usual range	63

Appears in

Sector: Health Care
Screens: Nuclear Stocks: Valuation Screen
Semiconductor Equipment Stocks: Valuation Screen

Screen Health Care stocks the same way

Research on ASND

No articles about ASND yet. How valuation percentiles work

Loading peers and related research…

About this history

What is ASND's current P/E?: Ascendis Pharma's P/E of 19.4x does not have enough weekly history to rank yet (as of Oct 30, 2026).
What is ASND's five-year median P/E?: There are not enough weekly readings yet for a five-year median P/E.
Does a low historical rank mean a stock is a buy?: No. The rank compares ASND only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.